dc.contributor.author | So, TMK | |
dc.contributor.author | Cakaloglu, Y | |
dc.contributor.author | Gerken, G | |
dc.contributor.author | Simon, C | |
dc.contributor.author | Janssen, HLA | |
dc.contributor.author | van Zonneveld, M | |
dc.contributor.author | Flink, HJ | |
dc.contributor.author | Verhey, E | |
dc.contributor.author | Senturk, H | |
dc.contributor.author | Zeuzem, S | |
dc.contributor.author | Akarca, US | |
dc.contributor.author | Schalm, SW | |
dc.contributor.author | Hansen, BE | |
dc.contributor.author | de Man, RA | |
dc.date.accessioned | 2021-03-02T22:21:49Z | |
dc.date.available | 2021-03-02T22:21:49Z | |
dc.date.issued | 2005 | |
dc.identifier.citation | van Zonneveld M., Flink H., Verhey E., Senturk H., Zeuzem S., Akarca U., Cakaloglu Y., Simon C., So T., Gerken G., et al., "The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation", ALIMENTARY PHARMACOLOGY & THERAPEUTICS, cilt.21, sa.9, ss.1163-1171, 2005 | |
dc.identifier.issn | 0269-2813 | |
dc.identifier.other | av_0c3ad19c-21b5-48fd-a03e-068dcd0c41b0 | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/13877 | |
dc.identifier.uri | https://doi.org/10.1111/j.1365-2036.2005.02453.x | |
dc.description.abstract | Background: Treatment with interferon-alpha has been shown to be effective in one-third of hepatitis B e antigen-positive chronic hepatitis B patients, but is clinically associated with relevant adverse events. | |
dc.language.iso | eng | |
dc.subject | Sağlık Bilimleri | |
dc.subject | İç Hastalıkları | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | GASTROENTEROLOJİ VE HEPATOLOJİ | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | FARMAKOLOJİ VE ECZACILIK | |
dc.subject | Farmakoloji ve Toksikoloji | |
dc.subject | Yaşam Bilimleri (LIFE) | |
dc.subject | Tıp | |
dc.subject | Temel Bilimler | |
dc.subject | Yaşam Bilimleri | |
dc.subject | Temel Eczacılık Bilimleri | |
dc.subject | Eczacılık | |
dc.subject | Gastroenteroloji-(Hepatoloji) | |
dc.title | The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation | |
dc.type | Makale | |
dc.relation.journal | ALIMENTARY PHARMACOLOGY & THERAPEUTICS | |
dc.contributor.department | , , | |
dc.identifier.volume | 21 | |
dc.identifier.issue | 9 | |
dc.identifier.startpage | 1163 | |
dc.identifier.endpage | 1171 | |
dc.contributor.firstauthorID | 175191 | |